scholarly journals Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first‐line antihypertensive therapy

2021 ◽  
Author(s):  
Revathy Carnagarin ◽  
Janis M. Nolde ◽  
Natalie C. Ward ◽  
Leslie Marisol Lugo‐Gavidia ◽  
Justine Chan ◽  
...  
Keyword(s):  
Antihypertensive Therapy ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
First Line

scholarly journals Clinical profile and drug therapy of outpatients with arterial hypertension

2020 ◽  
Vol 16 (2) ◽  
pp. 206-212
Author(s):  
N. V. Izmozherova ◽  
A. A. Popov ◽  
V. M. Bakhtin ◽  
M. A. Shambatov
Keyword(s):  
Arterial Hypertension ◽  
Antiplatelet Therapy ◽  
Antihypertensive Therapy ◽  
Antihypertensive Treatment ◽  
Myocardial Hypertrophy ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Mean Value ◽  
Target Organ ◽  
Very High

Aim. To study clinical profile and antihypertensive treatment features in outpatients observed in ambulatory facilities.Material and methods. 140 arterial hypertension (AH) outpatients were examined, questioning and anthropometry were performed. Blood pressure (BP) was measured on both hands, then twice on the hand with larger value, the medium value was calculated. Tests results were obtained from outpatient cards.Results. The sampling included 100 (71.4%) females and 40 (28.6%) males. Median of systolic BP at first measurement was 140.0 mm Hg (130.0;150.0), mean value of three BP measurements was 138.0 mm Hg (127.0;150.0) (p<0.001); median diastolic BP at first measurement was 83.0 mm Hg (80.0;90.0), mean BP value was 82.0 mm Hg (78.0;88.0) (p<0.001). Grade 1 AH was identified in 11.4% of patients, Grade 2 – in 35.7%, Grade 3 in 52.9%. No target organ damage was found in 26.4% of AH patients, asymptomatic target organ damage was diagnosed in 26.4%, and 61.4% had associated clinical conditions. Cardiovascular event risk was assessed as moderate in 13.6%, high – in 24.3% and very high – in 62.1% of patients. Every third patient had myocardial hypertrophy signs; Cornell index was detected more often than Sokolov-Layon index (p=0.006). Chronic kidney disease was diagnosed in 65.1% of patients: 44.0% of them had stage C2, 13.8% – stage C3A, 6.5% – stage C3B, and 1.8% – stage C4. 97.9% of AH patients received antihypertensive treatment. Daily medication consumption was reported by 127 people, and 10 patients reported taking medication as needed. Monotherapy was prescribed in 14.3% of patients; combined treatment was performed in 83.6% people. BP target value was achieved in 59 patients (42.1%) at first measurement results and in 71 (50.7%) ones at calculated mean value (p=0.002). Indications for statin use were identified in 86.4% of patients. Statins were administered in 56.2% patients having indications and in 21.1% of subjects without indications (p=0.006). Indications for antiplatelet therapy use were identified in 56.4% of patients. Antiplatelet treatment was administered in 58.2% of patients with indications and in 23.0% of subjects without indications (p<0.001).Conclusion. Glomerular filtration rate and left ventricular myocardial hypertrophy amplitude criteria calculation allow to diagnose subclinical target organ damage in outpatients at physician visit without additional costs. Compliance with the current antihypertensive therapy guidelines allows to achieve target BP in current practice. Compliance with the BP measuring rules allows to adequately assess the effectiveness of antihypertensive therapy. A significant proportion of AH outpatients have a very high cardiovascular risk, which requires lipid-lowering and antiplatelet therapy.

scholarly journals Antihypertensive Pharmacotherapy in Correcting the Indicators of Innate Immunity in Patients with Essential Arterial Hypertension

2020 ◽  
Vol 6 (4) ◽  
pp. 13-18
Author(s):  
Evgeniia V. Gavriliouk ◽  
IrinaIrina V. Evsegneeva ◽  
Vadim P. Mikhin
Keyword(s):  
Innate Immunity ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Left Ventricular ◽  
Target Organ ◽  
Vascular Lesions ◽  
Left Ventricular Myocardium ◽  
Essential Arterial Hypertension

Introduction: The study of indicators of innate immunity in patients with arterial hypertension in clinical trials makes it necessary to correct them in order to reduce vascular inflammation in arterial hypertension to prevent damage to target organs and development of cardiovascular complications. The aim of the study was to assess the effectiveness of antihypertensive therapy to correct indicators of innate immunity in patients with essential arterial hypertension. Materials and methods: Patients with essential arterial hypertension (EAH) (II stage, 3rd degree) were divided into 3 groups: the 1st group included the patients with hypertrophy of the left ventricular myocardium; the 2nd group included the patients with atherosclerotic vascular lesions; the 3rd group included the patients with chronic kidney disease. As an initial antihypertensive pharmacotherapy, all the patients with essential arterial hypertension were prescribed perindopril (5–10 mg/day) and amlodipine (5–10 mg/day). Results and discussion: Changes in innate immunity indices in patients with essential arterial hypertension (II stage, 3rd degree) are differentiated depending on the affected target organ. The antihypertensive pharmacotherapy with perindopril and amlodipine in patients with essential arterial hypertension has various corrective effects on impaired innate immunity, depending on the nature of target organ damage. Regardless of target organ damage, ноу antihypertensive therapy with perindopril and amlodipine does not affect the reduced functional and increased metabolic activities of peripheral blood neutrophils. Conclusion: The results obtained dictate the need for further clinical studies of other classes of antihypertensive drugs and their combinations in the correction of innate immunity indices in order to effectively prevent the progression of target organ damage. Graphical abstract

scholarly journals Approaches to the treatment of uncontrolled hypertension. Place of the Physiotens®

2021 ◽  
Vol 26 (6) ◽  
pp. 4535
Author(s):  
S. N. Tereshchenko ◽  
V. V. Ruksin ◽  
N. I. Gaponova ◽  
O. N. Tkacheva ◽  
D. V. Duplyakov ◽  
...  
Keyword(s):  
Antihypertensive Therapy ◽  
Target Organ Damage ◽  
Hypertensive Crisis ◽  
Organ Damage ◽  
International Classification Of Diseases ◽  
Target Organ ◽  
Uncontrolled Hypertension ◽  
Russian Society ◽  
Classification Of Diseases ◽  
Icd 10

The paper discusses the issues of managing uncontrolled hypertension. It is noted that in the International Classification of Diseases, 10th revision (ICD-10), there is no diagnosis “hypertensive crisis”, which complicates the epidemiological estimates. In the new Russian Society of Cardiology guidelines, instead of using the term “uncomplicated hypertensive crisis”, the term “sudden pronounced individually relevant blood pressure (BP) increase” was proposed to describe pronounced BP increase without target organ damage. Since the term “uncomplicated hypertensive crisis” is not recommended for use, but this condition is often diagnosed in practice, it is advisable to replace this term with “sharp BP increase not accompanied by target organ damage” or “sudden pronounced individually relevant BP increase”. At the same time, there is no evidence that in patients with uncomplicated hypertensive crisis, a more rapid BP decrease is more effective over the standard antihypertensive therapy in relation to the risk of complications. The drug Physiotens® lowers BP smoothly and without sudden falls, while having favorable pharmacokinetics. The issues of revising the current approaches to antihypertensive therapy in patients with frequent BP increases, as well as the use of original drugs and generics are considered.

Demographic and Clinical Characteristics of Hypertensive and/or Diabetic Patients with Target Organ Damage in the Lebanese Population

2020 ◽  
Vol 04 (06) ◽  
Author(s):  
Jeannot Kekedjian ◽  
Raymond Challita ◽  
Mikael Abi Abdallah ◽  
Roland Asmar ◽  
Mirna N Chahine
Keyword(s):  
Clinical Characteristics ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
Diabetic Patients ◽  
Lebanese Population

Inflammation and Target Organ Damage in Hypertension With or Without Metabolic Syndrome

2005 ◽  
Vol 12 (3) ◽  
pp. 175
Author(s):  
A. Ferrucci ◽  
S. Sciarretta ◽  
V. Venturelli ◽  
G. M. Ciavarella ◽  
P. De Paolis ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ

Ambulatory Blood Pressure, Target Organ Damage and Left Atrial Size in Never Treated Essential Hypertensives

2005 ◽  
Vol 12 (3) ◽  
pp. 156
Author(s):  
S. Meani ◽  
C. Cuspidi ◽  
C. Valerio ◽  
V. Fusi ◽  
E. Catini ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ambulatory Blood Pressure ◽  
Left Atrial ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
Blood Pressure Target ◽  
Left Atrial Size ◽  
Atrial Size
Sign in / Sign up

Export Citation Format

Share Document